Market Highlights
According
to MRFR analysis, Uveitis Treatment Market Size is expected to register a CAGR of 5.6% during
the forecast period of 2019 to 2025 and was valued at USD 534.6
million in 2018.
Uveitis
is an inflammation that occurs in the uvea. It is found in people aged between
20 to 50. Based on the origin of inflammation, uveitis categories in major
three types, namely, anterior uveitis, posterior uveitis, and intermediate
uveitis.
The
growth of the global Uveitis Treatment Market Size is determined by numerous
factors such as increasing research & development (R&D) expenditure,
rising prevalence of uveitis and continuous product launches. However,
side-effect related to corticosteroid drugs is projected to restrain the growth
of the market during the forecast period.
The
global Uveitis Treatment Market Size is currently dominated by several market
players. The key players are involved in expansion, product launches, and
strategic collaborations to strengthen their market positions.
Segmentation
The
global Uveitis Treatment Market Size has been segmented based on type, drug
class, and end-user.
The
market, based on type, has been divided into anterior uveitis, intermediate
uveitis, posterior uveitis, and others. The anterior uveitis is likely to hold
maximum market share in the global uveitis treatment market.
The global Uveitis Treatment Market Size based on drug class has been
segregated into corticosteroid drugs, anti-inflammatory drugs,
immunosuppressive drugs, and others. The corticosteroids drugs segment is
anticipated to hold the largest share in the market due to the rising
preference in the treatment of uveitis.
The end-user segments of the market are hospitals, specialty clinics,
and others. The hospital's segment is expected to hold the largest share of the
market, as these are the primary locations where patients receive treatment.
Key Players
Some of the key players in the Global Uveitis Treatment Market are
Allergan PLC, Novartis AG, Bausch Health, EyePoint Pharmaceuticals, Inc.,
AbbVie Inc., Horizon Therapeutics PLC, Mylan N.V., and Alimera Sciences.
Browse Full Report Details
@ https://www.marketresearchfuture.com/reports/uveitis-treatment-market-8457
Regional Analysis
The
market has been divided, by region, into the Americas, Europe, Asia-Pacific,
and the Middle East & Africa.
The
Americas are anticipated to hold the largest market share owing to the
increasing prevalence of uveitis, the presence of a well-established healthcare
sector, and high R&D expenditures. The Uveitis Treatment Market Size in the
Americas has further been branched into North America and Latin America, with
the North American market divided into the US and Canada.
The
European Uveitis Treatment Market Size has been categorized as Western Europe
and Eastern Europe. The Western European market has further been classified as
Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The Uveitis
Treatment Market Size in Asia-Pacific has been segmented into Japan, China,
India, South Korea, Australia, and the rest of Asia-Pacific. Due to the
presence of a large patient pool and expansion of healthcare facilities, the
market in Asia-Pacific is expected to be the fastest-growing. The Uveitis
Treatment Market Size in the Middle East & Africa has been divided into the
Middle East and Africa.
No comments:
Post a Comment